CryoPort Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY Revenue (est.)
$194.4Mnext fiscal year
FY EPS (est.)
-$0.73next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Supported Global Clinical Trials Quarterly766.0Target: Continued expansion of clinical pipeline
Commercially Approved Cell and Gene Therapies Supported Quarterly21.0Target: Up to 8 new therapy approvals expected in 2026
Commercial Cell and Gene Therapy Revenue Quarterly9.1MTarget: Double-digit year-over-year growth
Adjusted EBITDA from Continuing Operations Quarterly-600KTarget: Positive Adjusted EBITDA in the second half of 2026
Watch Items
- Path to Adjusted EBITDA ProfitabilityTrigger: Negative Adjusted EBITDA in H2 2026Action: Re-evaluate cost reduction initiatives, facility utilization, and pricing strategies across services and products segments.
- Customer Clinical Program DelaysTrigger: Decline in clinical trial support revenue growth below 10% year-over-yearAction: Assess commercial pipeline conversion rates and adjust capacity planning at global supply chain centers.
- Integration and Ramp-up of New FacilitiesTrigger: Delays in Paris BioServices (Q3 2026) or Santa Ana Global Supply Chain Center (Q4 2026) launchesAction: Review capital allocation and operational execution timelines to prevent capacity bottlenecks.
Research as of 19 Jun 2026